Trial Profile
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiretroviral Activity of MK-8507 in HIV-1 Infected Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Apr 2023
Price :
$35
*
At a glance
- Drugs Ulonivirine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 13 Oct 2021 Results published in the JAIDS
- 08 Oct 2020 Results presented at the 15th International Congress on Drug Therapy and HIV Infection
- 08 Oct 2020 Results presented in a Merck & Co Media Release.